Crinetics Announces January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces January 2023 inducement grants: the stock options were granted as inducements material to six employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference


Crinetics provides a company update at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11th at 3:00 p.m. Pacific Time

Crinetics Announces December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Crinetics Pharmaceuticals announces December 2022 inducement grants: the stock options were granted as inducements material to 12 employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4).

Crinetics Pharmaceuticals Provides Update on CRN04777 Program


Crinetics provided an update on development of CRN04777, an investigational, oral somatostatin receptor type 5 (SST5) agonist being developed as a treatment for congenital hyperinsulinism

Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference


Crinetics management will participate in a fireside chat on November 30, 2022 at the 5th Annual Evercore ISI HealthCONx Conference